{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:50:25Z","timestamp":1792713025483,"version":"4.5.0"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03140-0","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:40:21Z","timestamp":1778046021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CVOT Summit Report 2025: advances along the cardiovascular\u2013kidney\u2013metabolic disease continuum"],"prefix":"10.1186","volume":"25","author":[{"given":"Oliver","family":"Schnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Ballwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Barnard-Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Ballwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bl\u00fcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cebrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin M.","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Itzhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder K.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Korenjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Krentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Lambrinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F. E.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"M\u00fcller-Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh C.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F. H.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Reger-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M. C.","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Standl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Topsever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"3","key":"3140_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/ehjcvp\/pvw007","volume":"2","author":"F Zannad","year":"2016","unstructured":"Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):200\u20135.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"3140_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01575-9","volume":"21","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferovi\u0107 PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):144.","journal-title":"Cardiovasc Diabetol"},{"key":"3140_CR3","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1111\/j.1523-1755.2005.09906.x","volume":"99","author":"J Fort","year":"2005","unstructured":"Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl. 2005;99:S25\u20139.","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"3140_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"8","key":"3140_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082833","volume":"14","author":"V Mutruc","year":"2025","unstructured":"Mutruc V, Cristina B, Victori\u021ba \u0218, Alexandr C, Bianca Codrina M, Lauren\u021biu \u0218, et al. Cardiovascular\u2013Kidney\u2013Metabolic Syndrome: a new paradigm in clinical medicine or going back to basics? J Clin Med. 2025;14(8):2833.","journal-title":"J Clin Med"},{"issue":"10","key":"3140_CR6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135\u201346.","journal-title":"Drugs"},{"issue":"2","key":"3140_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1358\/dot.2021.57.2.3223386","volume":"57","author":"B Akinci","year":"2021","unstructured":"Akinci B. An update on dapagliflozin for the treatment of heart failure. Drugs Today (Barc). 2021;57(2):77\u201388.","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"3140_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/13696998.2023.2264715","volume":"26","author":"P McEwan","year":"2023","unstructured":"McEwan P, Hafner M, Jha V, Correa-Rotter R, Chernin G, De Nicola L, et al. Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis. J Med Econ. 2023;26(1):1407\u201316.","journal-title":"J Med Econ"},{"key":"3140_CR9","unstructured":"Federation ID. IDF Diabetes Atlas, 11th edn. Brussels. 2025. https:\/\/diabetesatlas.org\/media\/uploads\/sites\/3\/2025\/04\/IDF_Atlas_11th_Edition_2025.pdf. Accessed 23 Jan 2026."},{"issue":"4","key":"3140_CR10","volume":"47","author":"JA Vassalotti","year":"2025","unstructured":"Vassalotti JA, Francis A, Santos A, Correa-Rotter R, Abdellatif D, Hsiao LL, et al. Are your kidneys ok? Detect early to protect kidney health. Nephrology (Carlton). 2025;47(4):e20250106.","journal-title":"Nephrology (Carlton)"},{"issue":"11","key":"3140_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","volume":"32","author":"B Chong","year":"2025","unstructured":"Chong B, Figtree GA, Nicholls SJ, Mamas MA, Januzzi JL, Chew NWS, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2025;32(11):1001\u201315.","journal-title":"Eur J Prev Cardiol"},{"issue":"24","key":"3140_CR12","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"3140_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025;393(6):533\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"3140_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"issue":"18","key":"3140_CR15","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796\u2013806.","journal-title":"N Engl J Med"},{"issue":"10522","key":"3140_CR16","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","volume":"406","author":"DB Horn","year":"2025","unstructured":"Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927\u201344.","journal-title":"Lancet"},{"issue":"14","key":"3140_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393(14):1363\u201374.","journal-title":"N Engl J Med"},{"issue":"10510","key":"3140_CR18","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","volume":"406","author":"J Butler","year":"2025","unstructured":"Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025;406(10510):1341\u201350.","journal-title":"Lancet"},{"issue":"7","key":"3140_CR19","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1111\/dom.15608","volume":"26","author":"J Reed","year":"2024","unstructured":"Reed J, Dong T, Eaton E, Friswold J, Porges J, Al-Kindi SG, et al. Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: a clinical trial. Diabetes Obes Metab. 2024;26(7):2881\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"3140_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.pcd.2023.10.009","volume":"17","author":"R Edward","year":"2023","unstructured":"Edward R, Priefer R. A comparison of continuous glucose monitors (CGMs) in diabetes management: a systematic literature review. Prim Care Diabetes. 2023;17(6):529\u201334.","journal-title":"Prim Care Diabetes"},{"issue":"Suppl 7","key":"3140_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/dom.15921","volume":"26","author":"YW Kong","year":"2024","unstructured":"Kong YW, Morrison D, Lu JC, Lee MH, Jenkins AJ, O\u2019Neal DN. Continuous ketone monitoring: exciting implications for clinical practice. Diabetes Obes Metab. 2024;26(Suppl 7):47\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3140_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12933-025-02700-0","volume":"24","author":"O Schnell","year":"2025","unstructured":"Schnell O, Almandoz J, Anderson L, Barnard-Kelly K, Battelino T, Bl\u00fcher M, et al. CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2025;24(1):187.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12933-024-02180-8","volume":"23","author":"O Schnell","year":"2024","unstructured":"Schnell O, Barnard-Kelly K, Battelino T, Ceriello A, Larsson HE, Fern\u00e1ndez-Fern\u00e1ndez B, et al. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2024;23(1):104.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-023-01788-6","volume":"22","author":"O Schnell","year":"2023","unstructured":"Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, et al. CVOT Summit 2022 report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023;22(1):59.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12933-022-01481-0","volume":"21","author":"O Schnell","year":"2022","unstructured":"Schnell O, Battelino T, Bergenstal R, Bl\u00fcher M, B\u00f6hm M, Brosius F, et al. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol. 2022;21(1):50.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12933-021-01254-1","volume":"20","author":"O Schnell","year":"2021","unstructured":"Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-020-01022-7","volume":"19","author":"O Schnell","year":"2020","unstructured":"Schnell O, Standl E, Cos X, Heerspink HJ, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-019-0822-4","volume":"18","author":"O Schnell","year":"2019","unstructured":"Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th cardiovascular outcome trial (CVOT) summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019;18(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-018-0667-2","volume":"17","author":"O Schnell","year":"2018","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2018;17(1):30.","journal-title":"Cardiovasc Diabetol"},{"key":"3140_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-016-0357-x","volume":"15","author":"O Schnell","year":"2016","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3140_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-017-0508-8","volume":"16","author":"O Schnell","year":"2017","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2017;16(1):35.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"3140_CR32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3140_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","volume":"89","author":"JR Cerhan","year":"2014","unstructured":"Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami HO, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014;89(3):335\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"3140_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/24754269.2023.2205802","volume":"7","author":"T Ye","year":"2023","unstructured":"Ye T, Bannick M, Yi Y, Shao J. Robust variance estimation for covariate-adjusted unconditional treatment effect in randomized clinical trials with binary outcomes. Stat Theory Relat Fields. 2023;7(2):159\u201363.","journal-title":"Stat Theory Relat Fields"},{"issue":"11","key":"3140_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an oral small-molecule GLP-1 Receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065\u201376.","journal-title":"N Engl J Med"},{"issue":"20","key":"3140_CR36","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"issue":"7","key":"3140_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2502081","volume":"393","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, Bl\u00fcher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietil\u00e4inen KH, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393(7):635\u201347.","journal-title":"N Engl J Med"},{"issue":"7","key":"3140_CR38","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1056\/NEJMoa2502082","volume":"393","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. 2025;393(7):648\u201359.","journal-title":"N Engl J Med"},{"key":"3140_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100076","volume":"7","author":"HE Bays","year":"2023","unstructured":"Bays HE. Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review. Obes Pillars. 2023;7:100076.","journal-title":"Obes Pillars"},{"key":"3140_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040418","author":"N Piko","year":"2024","unstructured":"Piko N, Bevc S, Hojs R, Ekart R. Finerenone: from the mechanism of action to clinical use in kidney disease. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17040418.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3140_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","volume":"204","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract. 2023;204:110908.","journal-title":"Diabetes Res Clin Pract"},{"key":"3140_CR42","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Cherney D, Rossing P, Lawatscheck R, JB. M. Finerenone in CKD and Type 1 Diabetes [abstract]. Presented at American Society of Nephrology Kidney Week; November 6, 2025; Houston, TX. [Congress Session]. In press 2025.","DOI":"10.1681\/ASN.2025y0p1zsmv"},{"issue":"23","key":"3140_CR43","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"1 Suppl 1","key":"3140_CR44","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181-s206.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"3140_CR45","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","volume":"40","author":"RZ Alicic","year":"2025","unstructured":"Alicic RZ, Neumiller JJ, Tuttle KR. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant. 2025;40(Supplement_1):i3\u201317.","journal-title":"Nephrol Dial Transplant"},{"issue":"11\u201312","key":"3140_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14656566.2025.2547803","volume":"26","author":"P Stachteas","year":"2025","unstructured":"Stachteas P, Nasoufidou A, Karakasis P, Fragakis N, Patoulias D. Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease. Expert Opin Pharmacother. 2025;26(11\u201312):1255\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"3140_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","volume":"56","author":"M Horio","year":"2010","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56(1):32\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"10518","key":"3140_CR48","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","volume":"406","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Cardona JF, Jolly S, Pergola PE, de Sousa-Amorim E, Eriksson AL, et al. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. Lancet. 2025;406(10518):2449\u201360.","journal-title":"Lancet"},{"issue":"4","key":"3140_CR49","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41440-023-01188-z","volume":"46","author":"H Ando","year":"2023","unstructured":"Ando H. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors? Hypertens Res. 2023;46(4):1056\u20137.","journal-title":"Hypertens Res"},{"key":"3140_CR50","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000849","author":"JP Dwyer","year":"2025","unstructured":"Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, et al. Efficacy and safety of Baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2025. https:\/\/doi.org\/10.1681\/ASN.0000000849.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"3140_CR51","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41440-025-02297-7","volume":"48","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Jones ESW, Lihn AS, et al. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res. 2025;48(11):2911\u201323.","journal-title":"Hypertens Res"},{"key":"3140_CR52","unstructured":"Flack J, Azizi M, Brown J, Dwyer J, Jones E, Kurlyandskaya R, et al. Effect of baxdrostat on 24-hour average ambulatory blood pressure in patients with resistant hypertension: the Bax24 Trial [abstract]. Presented at: American Heart Association Scientific Sessions in November 09 2025, New Orleans, Louisiana. [Congress Session]. In press 2025."},{"issue":"5","key":"3140_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C, Fernandez Fernandez B, Ghali JK, Kopjar B, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial. JAMA. 2025;334(5):409\u201318.","journal-title":"JAMA"},{"key":"3140_CR54","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0183-2023","author":"RL Benza","year":"2024","unstructured":"Benza RL, Gr\u00fcnig E, Sandner P, Stasch JP, Simonneau G. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase. Eur Respir Rev. 2024. https:\/\/doi.org\/10.1183\/16000617.0183-2023.","journal-title":"Eur Respir Rev"},{"issue":"20","key":"3140_CR55","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"issue":"10510","key":"3140_CR56","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","volume":"406","author":"F Zannad","year":"2025","unstructured":"Zannad F, O\u2019Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025;406(10510):1351\u201362.","journal-title":"Lancet"},{"key":"3140_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cells14171400","author":"T Bajec","year":"2025","unstructured":"Bajec T, Poglajen G. Targeting the NO-sGC-cGMP pathway: mechanisms of action of Vericiguat in chronic heart failure. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14171400.","journal-title":"Cells"},{"key":"3140_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083039","volume":"390","author":"K Nong","year":"2025","unstructured":"Nong K, Jeppesen BT, Shi Q, Agoritsas T, Guyatt GH, White H, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025;390:e083039.","journal-title":"BMJ"},{"issue":"4","key":"3140_CR59","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.ajkd.2025.01.006","volume":"85","author":"A Ghimire","year":"2025","unstructured":"Ghimire A, Wanner C, Tonelli M. Closing CKD treatment gaps: why practice guidelines and better drug coverage are not enough. Am J Kidney Dis. 2025;85(4):406\u20138.","journal-title":"Am J Kidney Dis"},{"key":"3140_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1748-5908-8-35","volume":"8","author":"SA Flottorp","year":"2013","unstructured":"Flottorp SA, Oxman AD, Krause J, Musila NR, Wensing M, Godycki-Cwirko M, et al. A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. Implement Sci. 2013;8:35.","journal-title":"Implement Sci"},{"issue":"10304","key":"3140_CR61","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"(NCD-RisC) NRFC","year":"2021","unstructured":"(NCD-RisC) NRFC. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957\u201380.","journal-title":"Lancet"},{"issue":"12","key":"3140_CR62","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"4","key":"3140_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.pcd.2010.07.003","volume":"4","author":"A Zafar","year":"2010","unstructured":"Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes. 2010;4(4):203\u20137.","journal-title":"Prim Care Diabetes"},{"issue":"5","key":"3140_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15795","volume":"9","author":"T Dilles","year":"2023","unstructured":"Dilles T, Mortelmans L, Loots E, Sabbe K, Feyen H, Wauters M, et al. People-centered care and patients\u2019 beliefs about medicines and adherence: a cross-sectional study. Heliyon. 2023;9(5):e15795.","journal-title":"Heliyon"},{"issue":"7","key":"3140_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036575","volume":"10","author":"C Fitzpatrick","year":"2020","unstructured":"Fitzpatrick C, Gillies C, Seidu S, Kar D, Ioannidou E, Davies MJ, et al. Effect of pragmatic versus explanatory interventions on medication adherence in people with cardiometabolic conditions: a systematic review and meta-analysis. BMJ Open. 2020;10(7):e036575.","journal-title":"BMJ Open"},{"issue":"1","key":"3140_CR66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5694\/mja14.00002","volume":"201","author":"TC Hoffmann","year":"2014","unstructured":"Hoffmann TC, L\u00e9gar\u00e9 F, Simmons MB, McNamara K, McCaffery K, Trevena LJ, et al. Shared decision making: what do clinicians need to know and why should they bother? Med J Aust. 2014;201(1):35\u20139.","journal-title":"Med J Aust"},{"issue":"6","key":"3140_CR67","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1016\/S2352-3026(22)00131-4","volume":"9","author":"J Geissler","year":"2022","unstructured":"Geissler J, Huber S. Improving outcomes through patient-generated evidence-the next step in patient advocacy. Lancet Haematol. 2022;9(6):e399\u2013400.","journal-title":"Lancet Haematol"},{"key":"3140_CR68","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jama.2025.24288","volume":"335","author":"F Celletti","year":"2025","unstructured":"Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2025;335:434.","journal-title":"JAMA"},{"key":"3140_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120479","volume":"409","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Atherosclerosis. 2025;409:120479.","journal-title":"Atherosclerosis"},{"key":"3140_CR70","unstructured":"Hohneck A, Weing\u00e4rtner O. [ESC guidelines on dyslipidemia update 2025 : New recommendations for the practice]. Herz. 2025"},{"issue":"45","key":"3140_CR71","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1093\/eurheartj\/ehad583","volume":"44","author":"R Luengo-Fernandez","year":"2023","unstructured":"Luengo-Fernandez R, Walli-Attaei M, Gray A, Torbica A, Maggioni AP, Huculeci R, et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023;44(45):4752\u201367.","journal-title":"Eur Heart J"},{"key":"3140_CR72","doi-asserted-by":"crossref","unstructured":"Guenette J, Lacson R. Clinical decision support: point \u2013 closing gaps between evidence and practice to mitigate diagnostic error. AJR Am J Roentgenol. 2025","DOI":"10.2214\/AJR.25.33115"},{"issue":"11","key":"3140_CR73","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1111\/dom.70033","volume":"27","author":"RH Eckel","year":"2025","unstructured":"Eckel RH, Krentz AJ, Jacob S, Libby P. Global cardiometabolic alliance: a clinical and research initiative addressing the 21st century pandemic of insulin resistance-associated disease. Diabetes Obes Metab. 2025;27(11):6101\u20134.","journal-title":"Diabetes Obes Metab"},{"key":"3140_CR74","unstructured":"European Commission. Cardiovascular health. Available from: https:\/\/health.ec.europa.eu\/non-communicable-diseases\/cardiovascular-health_en. Accessed 04 Dec 2025."},{"key":"3140_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118528","volume":"396","author":"A Krentz","year":"2024","unstructured":"Krentz A, Jacob S, Heiss C, Sattar N, Lim S, Khunti K, et al. Rising to the challenge of cardio-renal-metabolic disease in the 21st century: translating evidence into best clinical practice to prevent and manage atherosclerosis. Atherosclerosis. 2024;396:118528.","journal-title":"Atherosclerosis"},{"issue":"7","key":"3140_CR76","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1111\/dom.16398","volume":"27","author":"YM Kang","year":"2025","unstructured":"Kang YM, Punov V, Lim S, Nauck MA. Comparative efficacy and tolerability of currently approved incretin mimetics: a systematic analysis of placebo-controlled clinical trials. Diabetes Obes Metab. 2025;27(7):3736\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"3140_CR77","first-page":"846","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025;48(5):846\u201359.","journal-title":"Diabetes Care"},{"issue":"6","key":"3140_CR78","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"key":"3140_CR79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","volume":"74","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annu Rev Med. 2023;74:125\u201339.","journal-title":"Annu Rev Med"},{"issue":"4","key":"3140_CR80","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.ackd.2021.06.001","volume":"28","author":"KL Tommerdahl","year":"2021","unstructured":"Tommerdahl KL, Nadeau KJ, Bjornstad P. Mechanisms of cardiorenal protection of glucagon-like peptide-1 receptor agonists. Adv Chronic Kidney Dis. 2021;28(4):337\u201346.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"3140_CR81","first-page":"429","volume":"75","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"10","key":"3140_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102637","volume":"13","author":"JL Harrington","year":"2025","unstructured":"Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, et al. Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions. JACC Heart Fail. 2025;13(10):102637.","journal-title":"JACC Heart Fail"},{"issue":"18","key":"3140_CR83","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med. 2025;392(18):1813\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"3140_CR84","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","volume":"40","author":"PK Judge","year":"2025","unstructured":"Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol Dial Transplant. 2025;40(6):1175\u201386.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3140_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067386","volume":"13","author":"N Tangri","year":"2023","unstructured":"Tangri N, Moriyama T, Schneider MP, Virgitti JB, De Nicola L, Arnold M, et al. Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 2023;13(5):e067386.","journal-title":"BMJ Open"},{"issue":"10424","key":"3140_CR86","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403(10424):379\u201390.","journal-title":"Lancet"},{"issue":"4","key":"3140_CR87","volume":"17","author":"AM Treihaft","year":"2025","unstructured":"Treihaft AM, Parikh MA, Jackson KA, Frishman WH, Peterson SJ. New therapies for the management of chronic kidney disease. Cureus. 2025;17(4):e81824.","journal-title":"Cureus"},{"key":"3140_CR88","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, et al. Rationale, design, and baseline characteristics of the TRANSCEND-CKD trial of Retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2025; gfaf230.","DOI":"10.1093\/ndt\/gfaf230"},{"key":"3140_CR89","doi-asserted-by":"publisher","first-page":"1389106","DOI":"10.3389\/fcvm.2024.1389106","volume":"11","author":"B Bashir","year":"2024","unstructured":"Bashir B, Schofield J, Downie P, France M, Ashcroft DM, Wright AK, et al. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia. Front Cardiovasc Med. 2024;11:1389106.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"3140_CR90","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"10289","key":"3140_CR91","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139.","journal-title":"Lancet"},{"issue":"4","key":"3140_CR92","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/cells10040951","volume":"10","author":"P Libby","year":"2021","unstructured":"Libby P. Targeting inflammatory pathways in cardiovascular disease: the inflammasome, interleukin-1, interleukin-6 and beyond. Cells. 2021;10(4):951.","journal-title":"Cells"},{"issue":"26","key":"3140_CR93","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497\u2013505.","journal-title":"N Engl J Med"},{"key":"3140_CR94","doi-asserted-by":"publisher","first-page":"1430236","DOI":"10.3389\/fphar.2024.1430236","volume":"15","author":"P Chen","year":"2024","unstructured":"Chen P, Li X. NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies. Front Pharmacol. 2024;15:1430236.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3140_CR95","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol. 2024;326(5):H1159\u201376.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"3140_CR96","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/ATVBAHA.124.320155","volume":"44","author":"H Ait-Oufella","year":"2024","unstructured":"Ait-Oufella H, Libby P. Inflammation and atherosclerosis: prospects for clinical trials. Arterioscler Thromb Vasc Biol. 2024;44(9):1899\u2013905.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"36","key":"3140_CR97","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"10354","key":"3140_CR98","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757\u201367.","journal-title":"Lancet"},{"issue":"3","key":"3140_CR99","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"10","key":"3140_CR100","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia"},{"issue":"10","key":"3140_CR101","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","volume":"136","author":"BA Kappel","year":"2017","unstructured":"Kappel BA, Lehrke M, Sch\u00fctt K, Artati A, Adamski J, Lebherz C, et al. Effect of empagliflozin on the metabolic signature of patients with Type 2 Diabetes Mellitus and cardiovascular disease. Circulation. 2017;136(10):969\u201372.","journal-title":"Circulation"},{"issue":"17","key":"3140_CR102","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S. Possible mechanism of hematocrit elevation by Sodium Glucose Cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985\u20137.","journal-title":"Circulation"},{"issue":"16","key":"3140_CR103","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"10458","key":"3140_CR104","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024;404(10458):1119\u201331.","journal-title":"Lancet"},{"issue":"11","key":"3140_CR105","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ejhf.3453","volume":"26","author":"LH Lund","year":"2024","unstructured":"Lund LH, James S, DeVore AD, Anstrom KJ, Fudim M, Aaronson KD, et al. The spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT-HFpEF): rationale and design. Eur J Heart Fail. 2024;26(11):2453\u201363.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"3140_CR106","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"5","key":"3140_CR107","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"11","key":"3140_CR108","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","volume":"31","author":"K Nadolsky","year":"2025","unstructured":"Nadolsky K, Garvey WT, Agarwal M, Bonnecaze A, Burguera B, Chaplin MD, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the evaluation and treatment of adults with Obesity\/Adiposity-Based Chronic Disease - 2025 Update. Endocr Pract. 2025;31(11):1351\u201394.","journal-title":"Endocr Pract"},{"issue":"9","key":"3140_CR109","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Halford JCG, Sbraccia P, Yumuk V, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024;30(9):2395\u20139.","journal-title":"Nat Med"},{"issue":"10520","key":"3140_CR110","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","volume":"406","author":"LK Billings","year":"2025","unstructured":"Billings LK, Hsia S, Bays H, Tidemann-Miller B, O\u2019Hagan J, Tham LS, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631\u201343.","journal-title":"Lancet"},{"issue":"Suppl 4","key":"3140_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"3140_CR112","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1111\/dom.15913","volume":"26","author":"RL Dubin","year":"2024","unstructured":"Dubin RL, Heymsfield SB, Ravussin E, Greenway FL. Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps. Diabetes Obes Metab. 2024;26(12):5503\u201318.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3140_CR113","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3140_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02176-w","volume":"29","author":"Z Jia","year":"2024","unstructured":"Jia Z, Wang Z, Pan H, Zhang J, Wang Q, Zhou C, et al. Crosstalk between fat tissue and muscle, brain, liver, and heart in obesity: Cellular and molecular perspectives. Eur J Med Res. 2024;29(1):637.","journal-title":"Eur J Med Res"},{"issue":"1","key":"3140_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14010012","volume":"14","author":"MM Syed-Abdul","year":"2023","unstructured":"Syed-Abdul MM. Lipid metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD). Metabolites. 2023;14(1):12.","journal-title":"Metabolites"},{"issue":"1","key":"3140_CR116","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"3140_CR117","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jcjd.2025.04.003","volume":"49","author":"J Kim","year":"2025","unstructured":"Kim J, Bajaj HS, Ramji A, Bemeur C, Sebastiani G. Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease in adults: a clinical practice guideline. Can J Diabetes. 2025;49(4):222\u201336.","journal-title":"Can J Diabetes"},{"issue":"24","key":"3140_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413238","volume":"25","author":"J Janssen","year":"2024","unstructured":"Janssen J. The causal role of ectopic fat deposition in the pathogenesis of metabolic syndrome. Int J Mol Sci. 2024;25(24):13238.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3140_CR119","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL E","year":"2024","unstructured":"EASL E, EASO. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"11","key":"3140_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70407","volume":"45","author":"S Petta","year":"2025","unstructured":"Petta S, Kim K, Targher G, Romeo S, Sookoian S, Zheng MH, et al. Focus on Semaglutide 2.4\u2009mg\/week for the treatment of metabolic dysfunction-associated steatohepatitis. Liver Int. 2025;45(11):e70407.","journal-title":"Liver Int"},{"issue":"6","key":"3140_CR121","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024;84(6):729\u201335.","journal-title":"Drugs"},{"key":"3140_CR122","unstructured":"Eurpoean Medicines Agency. Rezdiffra (resmetirom): European public assessment report. 2025 19.06.2025. Available from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rezdiffra-epar-public-assessment-report_en.pdf. Accessed on 19 Jan 2026."},{"issue":"4","key":"3140_CR123","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"3140_CR124","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"issue":"10520","key":"3140_CR125","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025;406(10520):2644\u201355.","journal-title":"Lancet"},{"issue":"10","key":"3140_CR126","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964\u201374.","journal-title":"Diabetes Care"},{"issue":"3","key":"3140_CR127","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2337\/diacare.26.3.832","volume":"26","author":"MW Steffes","year":"2003","unstructured":"Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care. 2003;26(3):832\u20136.","journal-title":"Diabetes Care"},{"key":"3140_CR128","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/176245","volume":"2008","author":"T Forst","year":"2008","unstructured":"Forst T, Kunt T, Wilhelm B, Weber MM, Pf\u00fctzner A. Role of C-peptide in the regulation of microvascular blood flow. Exp Diabetes Res. 2008;2008:176245.","journal-title":"Exp Diabetes Res"},{"issue":"3","key":"3140_CR129","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1900\/RDS.2009.6.168","volume":"6","author":"J Haidet","year":"2009","unstructured":"Haidet J, Cifarelli V, Trucco M, Luppi P. Anti-inflammatory properties of C-peptide. Rev Diabet Stud. 2009;6(3):168\u201379.","journal-title":"Rev Diabet Stud"},{"issue":"5","key":"3140_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127439","volume":"10","author":"JA Shaw","year":"2015","unstructured":"Shaw JA, Shetty P, Burns KD, Fergusson D, Knoll GA. C-peptide as a therapy for kidney disease: a systematic review and meta-analysis. PLoS ONE. 2015;10(5):e0127439.","journal-title":"PLoS ONE"},{"issue":"7","key":"3140_CR131","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An Anti-CD3 antibody, teplizumab, in relatives at risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603\u201313.","journal-title":"N Engl J Med"},{"issue":"21","key":"3140_CR132","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","volume":"383","author":"T Quattrin","year":"2020","unstructured":"Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, et al. Golimumab and beta-cell function in youth with new-onset Type 1 Diabetes. N Engl J Med. 2020;383(21):2007\u201317.","journal-title":"N Engl J Med"},{"issue":"23","key":"3140_CR133","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"Waibel M, Wentworth JM, So M, Couper JJ, Cameron FJ, MacIsaac RJ, et al. Baricitinib and \u03b2-cell function in patients with new-onset Type 1 Diabetes. N Engl J Med. 2023;389(23):2140\u201350.","journal-title":"N Engl J Med"},{"issue":"10510","key":"3140_CR134","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(25)01674-5","volume":"406","author":"C Mathieu","year":"2025","unstructured":"Mathieu C, Wych J, Hendriks AEJ, Van Ryckeghem L, Tree T, Chmura P, et al. Minimum effective low dose of antithymocyte globulin in people aged 5\u201325 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet. 2025;406(10510):1375\u201388.","journal-title":"Lancet"},{"issue":"12","key":"3140_CR135","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2023.2064","volume":"329","author":"GP Forlenza","year":"2023","unstructured":"Forlenza GP, McVean J, Beck RW, Bauza C, Bailey R, Buckingham B, et al. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA. 2023;329(12):990\u20139.","journal-title":"JAMA"},{"issue":"6","key":"3140_CR136","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00125-024-06124-5","volume":"67","author":"ML Marcovecchio","year":"2024","unstructured":"Marcovecchio ML, Hendriks AEJ, Delfin C, Battelino T, Danne T, Evans ML, et al. The INNODIA Type 1 Diabetes natural history study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia. 2024;67(6):995\u20131008.","journal-title":"Diabetologia"},{"issue":"1","key":"3140_CR137","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088522","volume":"15","author":"L Hoffmann","year":"2025","unstructured":"Hoffmann L, Kohls M, Arnolds S, Achenbach P, Bergholdt R, Bonifacio E, et al. EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. BMJ Open. 2025;15(1):e088522.","journal-title":"BMJ Open"},{"issue":"23","key":"3140_CR138","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2024.06.050","volume":"84","author":"C Gyldenkerne","year":"2024","unstructured":"Gyldenkerne C, Kahlert J, Thrane PG, Olesen KKW, Mortensen MB, S\u00f8rensen HT, et al. 2-Fold more cardiovascular disease events decades before type 2 diabetes diagnosis: a Nationwide Registry Study. J Am Coll Cardiol. 2024;84(23):2251\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3140_CR139","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00125-020-05377-0","volume":"64","author":"S Burgess","year":"2021","unstructured":"Burgess S, Malik R, Liu B, Mason AM, Georgakis MK, Dichgans M, et al. Dose-response relationship between genetically proxied average blood glucose levels and incident coronary heart disease in individuals without diabetes mellitus. Diabetologia. 2021;64(4):845\u20139.","journal-title":"Diabetologia"},{"issue":"6","key":"3140_CR140","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1111\/dom.16304","volume":"27","author":"JH Ko","year":"2025","unstructured":"Ko JH, Moon SJ, Ajjan RA, Lee MY, Lee HJ, Choi B, et al. Workplace-based continuous glucose monitoring with structured education for pre-diabetes and type 2 diabetes: a prospective community cohort study. Diabetes Obes Metab. 2025;27(6):2996\u20133005.","journal-title":"Diabetes Obes Metab"},{"issue":"1 Suppl 1","key":"3140_CR141","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.2337\/dc26-SREV","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. Summary of revisions: standards of care in diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-s12.","journal-title":"Diabetes Care"},{"issue":"4","key":"3140_CR142","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1111\/dom.16212","volume":"27","author":"J Cai","year":"2025","unstructured":"Cai J, Liu J, Lu J, Ni J, Wang C, Chen L, et al. Impact of time in tight range on all-cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study. Diabetes Obes Metab. 2025;27(4):2154\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"3140_CR143","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1111\/dom.16511","volume":"27","author":"M Inoue","year":"2025","unstructured":"Inoue M, Kusunoki Y, Ohigashi M, Osugi K, Inoue C, Otsuka A, et al. Continuous glucose monitoring-derived time in range is associated with changes in cognitive function test scores in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2025;27(9):4737\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"3140_CR144","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1111\/jdi.70161","volume":"16","author":"J Bao","year":"2025","unstructured":"Bao J, Xu T, Gu T, Sun Y, Jiang Y, Xiao J, et al. Correlation between time in range and mild cognitive impairment in older adults with type 2 diabetes mellitus. J Diabetes Investig. 2025;16(12):2225\u201333.","journal-title":"J Diabetes Investig"},{"issue":"2","key":"3140_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101616","volume":"51","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Xiao S, Zou F, Jiao X, Shen Y. Continuous glucose monitoring-derived time in range and CV are associated with elevated risk of adverse kidney outcomes for patients with type 2 diabetes. Diabetes Metab. 2025;51(2):101616.","journal-title":"Diabetes Metab"},{"issue":"3","key":"3140_CR146","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/dia.2024.0404","volume":"27","author":"BP Kovatchev","year":"2025","unstructured":"Kovatchev BP, Lobo B, Fabris C, Ganji M, El Fathi A, Breton MD, et al. The virtual DCCT: adding continuous glucose monitoring to a landmark clinical trial for prediction of microvascular complications. Diabetes Technol Ther. 2025;27(3):209\u201316.","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"3140_CR147","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.2337\/dc20-1690","volume":"44","author":"R Roussel","year":"2021","unstructured":"Roussel R, Riveline JP, Vicaut E, de Pouvourville G, Detournay B, Emery C, et al. Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: The RELIEF study. Diabetes Care. 2021;44(6):1368\u201376.","journal-title":"Diabetes Care"},{"issue":"5","key":"3140_CR148","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/1932296818822986","volume":"13","author":"MH Lee","year":"2019","unstructured":"Lee MH, Paldus B, Krishnamurthy B, McAuley SA, Shah R, Jenkins AJ, et al. The clinical case for the integration of a ketone sensor as part of a closed loop insulin pump system. J Diabetes Sci Technol. 2019;13(5):967\u201373.","journal-title":"J Diabetes Sci Technol"},{"issue":"10","key":"3140_CR149","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0180","volume":"12","author":"H Zelada","year":"2023","unstructured":"Zelada H, Perez-Guzman MC, Chernavvsky DR, Galindo RJ. Continuous glucose monitoring for inpatient diabetes management: an update on current evidence and practice. Endocr Connect. 2023;12(10):e230180.","journal-title":"Endocr Connect"},{"issue":"4","key":"3140_CR150","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1177\/19322968211008185","volume":"15","author":"S Alva","year":"2021","unstructured":"Alva S, Castorino K, Cho H, Ou J. Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor. J Diabetes Sci Technol. 2021;15(4):768\u201374.","journal-title":"J Diabetes Sci Technol"},{"issue":"10","key":"3140_CR151","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11892-022-01489-6","volume":"22","author":"M Jaromy","year":"2022","unstructured":"Jaromy M, Miller JD. Potential clinical applications for continuous ketone monitoring in the hospitalized patient with diabetes. Curr Diab Rep. 2022;22(10):501\u201310.","journal-title":"Curr Diab Rep"},{"issue":"9468","key":"3140_CR152","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415\u201328.","journal-title":"Lancet"},{"issue":"6","key":"3140_CR153","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","volume":"478","author":"K Ramasubbu","year":"2023","unstructured":"Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem. 2023;478(6):1307\u201324.","journal-title":"Mol Cell Biochem"},{"issue":"10366","key":"3140_CR154","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/S0140-6736(22)02350-9","volume":"400","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Tsch\u00f6p MH. Gut-hormone triple agonists: clinical safety and metabolic benefits. Lancet. 2022;400(10366):1826\u20138.","journal-title":"Lancet"},{"issue":"6","key":"3140_CR155","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","volume":"5","author":"R Nogueiras","year":"2023","unstructured":"Nogueiras R, Nauck MA, Tsch\u00f6p MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat Metab. 2023;5(6):933\u201344.","journal-title":"Nat Metab"},{"issue":"8","key":"3140_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/cells14080564","volume":"14","author":"E Standl","year":"2025","unstructured":"Standl E, Schnell O. Increased risk of cancer-an integral component of the cardio-renal-metabolic disease cluster and its management. Cells. 2025;14(8):564.","journal-title":"Cells"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03140-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03140-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:14:09Z","timestamp":1778109249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03140-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3140"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03140-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OS (Oliver Schnell) is the founder and CEO of Sciarc and reports consulting, speaking, or serving on advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, and W\u00f6rwag Pharma. AA (Arnav Argawal) has nothing reported. MA (Michel Azizi) has nothing reported. DB (Dennis Ballwieser) reports no conflicts of interest. KBK (Katharine Barnard-Kelly) is a founder and shareholder of Spotlight-AQ and a Director of WellFight non-profit. She has received research funding from Dexcom, Lilly, Abbott, Braun Institute, EU Horizons, and honoraria from Abbott, Dexcom, and Embecta. TB (Tadej Battelino) has nothing reported. MB (Matthias Bl\u00fcher) received honoraria as a consultant and speaker from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi\u2013Sankyo, Lilly, MSD, Novo Nordisk, Novartis, Pfizer, and Sanofi; and reports chairing a Clinical Trial Data Safety Monitoring Board for Boehringer Ingelheim. EB (Elisabetta Bugianesi) is a consultant for Eli Lilly, Novo Nordisk, Boehringer, and MSD. ACb (Ana Cebrian) declares funding to conduct clinical trials from MSD and Sanofi (all to the IMIB institute); she received consulting fees from AstraZeneca, Bayer, Eli Lilly, MSD, Novo Nordisk, and Sanofi; payment of honoraria for lectures from AstraZeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, Menarini, MSD, Sanofi and Novo Nordisk. ACr (Antonio Ceriello) has received honoraria by Abbott, Bayer, Berlin Chemie, Boehringer Ingelheim, Cipla, Hikamar Pharma, Guidotti, Eli Lilly, MSD, Merck, Novo Nordisk, Sanofi, Servier, and SUN Pharma. PC (Pratik Choudhary) has nothing reported. TD (Thomas Danne) has nothing reported. CMD (Colin M. Dayan) has nothing reported. SDP (Stefano Del Prato) has nothing reported. RHE (Robert H. Eckel) has nothing reported. PF (Paola Fioretto) has nothing reported. TG (Timothy Garvey) has nothing reported. JBG\u2019s (Jennifer B. Green) research is supported by Boehringer Ingelheim, Merck, GentiBio, Cour, and Metsera. JBG consulted Bayer, Boehringer Ingelheim, Corcept, Vertex, Valo, vTv, Lilly, Merck, Mineralys, Novo Nordisk, Zealand, Idorsia, and Sparrow. HJLH (Hiddo J.L. Heerspink) has nothing reported. RRH (Rury R. Holman) has nothing reported. BI (Baruch Itzhak) has nothing reported. SJ (Stephan Jacob) has nothing reported. PSJ (Pardeep S. Jhund) reports speakers\u2019 fees from AstraZeneca, ProAdWise Communications; advisory board fees from AstraZeneca, Novo Nordisk, Bayer AG; research funding from AstraZeneca, Analog Devices Inc, Roche Diagnostics. PSJ\u2019s employer, the University of Glasgow, has been remunerated for clinical trial work from AstraZeneca, Bayer AG, Novartis and Novo Nordisk, and is a Director of GCTP Ltd. LJ (Linong Ji) reports receiving consulting or lecture fees from Eli Lilly, Novo Nordisk, Merck, Bayer, Sanofi-Aventis, MSD, AstraZeneca, Boehinger Ingelheim, Abbott, Fosun Pharma, Innovent Biologics, Gan & Lee Pharmaceuticals, Sinocare, and Sibionics. PKJ (Parminder K. Judge) declares a grant to the University of Oxford from Boehringer Ingelheim for the EASi-KIDNEY trial. KK (Kamlesh Khunti) has nothing reported. MK (Marko Korenjak) has nothing reported. AJK (Andrew J. Krentz) has nothing reported. EL (Ekaterini Lambrinou) has nothing to declare. PL (Peter Libby) is an unpaid consultant to, or involved in clinical trials for Abcentra, Amgen, DrugFarm, Esperion, Incyte, Kowa, Novartis, NovoNordisk, Ventyx. PL is a member of the scientific advisory board for Abcentra, Amgen, Novartis, Olatec, Xbiotech, Polygon, and Soley Therapeutics. PL\u2019s laboratory has received research funding in the last 2\u00a0years from Novartis, Novo Nordisk, and Genentech. PL declines all personal compensation from pharma or device companies. PL is on the Board of Directors of Abcentra, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. PL\u2019s interests were reviewed and are managed by Brigham and Women\u2019s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. PL receives funding support from the National Heart, Lung, and Blood Institute (R01HL170000, 1R01HL163099-01, R01AG063839, R01HL151627, R01HL157073, R01HL166538), and the RRM Charitable Fund. JKM (Julia K. Mader) is a member of advisory boards of Abbott Diabetes Care, Becton\u2013Dickinson, Biomea Fusion, Dexcom, Eli Lilly, Embecta, Insulet, Medtronic, myLife, Novo Nordisk A\/S, Pharmasens, Roche Diabetes Care, Sanofi-Aventis, Tandem, Viatris, and received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, Dexcom, Eli Lilly, Medtrust, MSD, Novo Nordisk A\/S, Roche Diabetes Care, Sanofi, Sinocare, Viatris, and Ypsomed. JKM is a shareholder of decide Clinical Software GmbH and elyte Diagnostics and serves as CMO of elyte Diagnostics. JFEM (Johannes F.E. Mann) has received honoraria from Cytel, Icon, Iqvia, Parexel, WCG, Sanofi, Hexal, and Novo Nordisk. NM (Nikolaus Marx) reports honoraria for lectures from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, Sanofi, and for consulting from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Novo Nordisk, and Sanofi. NM received research grants from Boehringer Ingelheim and Novo Nordisk. CM (Chantal Mathieu) serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB Bio, vTv Therapeutics and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Dexcom, Novo Nordisk, and Sanofi; CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Insulet, Abbott, Vertex, and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is president of EUDF. All external support of EUDF is to be found on\n                      \n                      . JJVM (John J.V. McMurray) has nothing reported. DMW (Dirk M\u00fcller-Wieland) is on advisory boards and has served on the speaker bureau for Amarin, Amgen, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Lilly, MSD, Novartis, Novo Nordisk, Oviva, Sanofi, and Sobi. NP (Nikolaos Papanas) has been an advisory board member of Astra-Zeneca, Bayer, BoehringerIngelheim, Menarini, MSD, Novo Nordisk, Pfizer, Roche, Takeda and TrigoCare International; has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for Astra-Zeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, ELPEN, Galenica, KRKA, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda, Viatris and Vianex; and attended conferences sponsored by TrigoCare International, Bayer, Eli-Lilly, Galenica, Novo Nordisk, Pfizer, Viatris and Sanofi-Aventis. DCP (Dipesh C. Patel) provides advisory and educational work for Eli-Lilly, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. He is a senior advisor at Reset health and digital weight management platform- Roczen. AFHP (Andreas F.H. Pfeiffer) has nothing reported. SRT (Susanne Reger-Tan) reports honoraria for lectures from Abbott, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Sanofi Aventis, and SinoCare, for consulting and advisory from Abbott, Boehringer-Ingelheim, Dexcom, Insulet, Novo Nordisk, Sanofi Aventis, SinoCare, and funded research from Abbott, Amgen, Apo Science, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Hoffmann-La Roche, Medtronic, NeoplasMed, Novartis, Novo Nordisk. HWR (Helena W. Rodbard) has nothing reported. GMCR (Giuseppe M.C. Rosano) was supported by Grant Ricerca Corrente, Italian Ministry of Health. BS (Banshi Saboo) has nothing reported. NS (Naoki Sato) received Honoraria and consulted Otsuka, Novartis, Bayer, Terumo, Boehringer-Ingelheim, Daiichi-Sankyo, AstraZeneca, Bristol Myers Squibb, Abiomed, and Medtronic. SDS (Scott D. Solomon) has nothing reported. ES (Eberhard Standl) reports personal fees from Oxford Diabetes Trials Unit, Bayer, Berlin Chemie, Boehringer Ingelheim, Menarini, Merck Serono, EXCEMED, Novartis, Novo Nordisk, and Sanofi. FT\u2019s (Frank Tacke) lab has received research grants (funding to the institution) from AstraZeneca, MSD, Gilead, and Agomab. FT has received honoraria for consulting or lectures from Gilead, AbbVie, Falk, AstraZeneca, Boehringer, Mirum, Madrigal, MSD, GSK, Ipsen, Pfizer, Novartis, Novo Nordisk, and Sanofi. FT is supported by the German Research Foundation (DFG CRC\/TR 412, Project-ID 535081457, and SFB1382, Project-ID 403224013) and under Germany\u2019s Excellence Strategy \u2013 EXC 3118\/1 \u2013 project number 533770413. PT (Pinar Topsever) has nothing reported. CW (Christoph Wanner) received honoraria for steering committee membership, advisory board membership and lecturing from Alexion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL-Vifor, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, and Vera. SW (Sean Wharton) received honoraria from or served on advisory boards at Abbvie, Amgen, AstraZeneca, Bausch Health Canada, Boehringer Ingelheim, Eli Lilly, i2o Therapeutics, Merck, Metsera, NGX, Novo Nordisk, and Regeneron. SW was\/is involved in research sponsored by Amgen, AstraZeneca, Bausch Health Canada, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Pfizer. SW is part of the McMaster University, York University, University of Toronto, Obesity Canada. VY (Veronika Young) is an employee of Sciarc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}